Manders E, van den Berg S, de Visser S, Hollak C
Eur J Health Econ. 2024; .
PMID: 39495345
DOI: 10.1007/s10198-024-01731-w.
Mancuso S, Bhalerao A, Cucullo L
Int J Mol Sci. 2024; 25(20).
PMID: 39456783
PMC: 11506837.
DOI: 10.3390/ijms252011000.
Basso V, Dobrossy M, Thompson L, Kirik D, Fuller H, Gates M
Biology (Basel). 2024; 13(9).
PMID: 39336117
PMC: 11428604.
DOI: 10.3390/biology13090690.
Quinn T, Bruce A, Burt T, Dhaliwal K
BMC Pulm Med. 2024; 24(1):425.
PMID: 39210357
PMC: 11363577.
DOI: 10.1186/s12890-024-03193-5.
Ansar Khawaja S, Farooq M, Ishaq K, Alsubaie N, Karamti H, Montero E
BMC Cancer. 2024; 24(1):900.
PMID: 39060972
PMC: 11282659.
DOI: 10.1186/s12885-024-12609-8.
Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment.
Zeng Q, Hu H, Huang Z, Guo A, Lu S, Tong W
Front Mol Biosci. 2024; 11:1413214.
PMID: 38919748
PMC: 11196408.
DOI: 10.3389/fmolb.2024.1413214.
Assessing drug lag in new drug approvals by the Iran Food and Drug Administration compared to the U.S. FDA, EMA, and PMDA: A 20-year analysis (2001-2021).
Alipour S, Nadimi Parashkouhi S, Mojahedian M, Abbasian H
Medicine (Baltimore). 2024; 103(25):e38142.
PMID: 38905367
PMC: 11191854.
DOI: 10.1097/MD.0000000000038142.
Antifungal and antibiofilm effect of duloxetine hydrochloride against Cryptococcus neoformans and Cryptococcus gattii.
Rehem A, da Gama Viveiro L, De Souza Santos E, Fonseca Do Carmo P, Da Silva N, Junqueira J
Folia Microbiol (Praha). 2024; 69(6):1247-1254.
PMID: 38652436
DOI: 10.1007/s12223-024-01164-1.
DPI_CDF: druggable protein identifier using cascade deep forest.
Arif M, Fang G, Ghulam A, Musleh S, Alam T
BMC Bioinformatics. 2024; 25(1):145.
PMID: 38580921
PMC: 11334562.
DOI: 10.1186/s12859-024-05744-3.
A comprehensive review of discovery and development of drugs discovered from 2020-2022.
Shareef U, Altaf A, Ahmed M, Akhtar N, Almuhayawi M, Al Jaouni S
Saudi Pharm J. 2024; 32(1):101913.
PMID: 38204591
PMC: 10777120.
DOI: 10.1016/j.jsps.2023.101913.
The clinical trials puzzle: How network effects limit drug discovery.
Vasan K, Morselli Gysi D, Barabasi A
iScience. 2023; 26(12):108361.
PMID: 38146432
PMC: 10749231.
DOI: 10.1016/j.isci.2023.108361.
Rapid Prototyping of Thermoplastic Microfluidic 3D Cell Culture Devices by Creating Regional Hydrophilicity Discrepancy.
Bai H, Olson K, Pan M, Marshall T, Singh H, Ma J
Adv Sci (Weinh). 2023; 11(7):e2304332.
PMID: 38032118
PMC: 10870023.
DOI: 10.1002/advs.202304332.
Mechanism of the antidiabetic action of and Thymoquinone: a review.
Shaukat A, Zaidi A, Anwar H, Kizilbash N
Front Nutr. 2023; 10:1126272.
PMID: 37818339
PMC: 10561288.
DOI: 10.3389/fnut.2023.1126272.
Multiple modes of data sharing can facilitate secondary use of sensitive health data for research.
Tamuhla T, Lulamba E, Mutemaringa T, Tiffin N
BMJ Glob Health. 2023; 8(10).
PMID: 37802544
PMC: 10565310.
DOI: 10.1136/bmjgh-2023-013092.
Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design.
Vora L, Gholap A, Jetha K, Thakur R, Solanki H, Chavda V
Pharmaceutics. 2023; 15(7).
PMID: 37514102
PMC: 10385763.
DOI: 10.3390/pharmaceutics15071916.
Raising the curtain: from the gut lumen to human health and disease-the point of interest for internal medicine.
Ciccocioppo R, Portincasa P
Intern Emerg Med. 2023; 18(5):1255-1258.
PMID: 37420085
DOI: 10.1007/s11739-023-03326-4.
The future of clinical trials and drug development: 2050.
Hardman T, Aitchison R, Scaife R, Edwards J, Slater G
Drugs Context. 2023; 12.
PMID: 37313038
PMC: 10259497.
DOI: 10.7573/dic.2023-2-2.
TLSEA: a tool for lncRNA set enrichment analysis based on multi-source heterogeneous information fusion.
Li J, Li Z, Wang Y, Lin H, Wu B
Front Genet. 2023; 14:1181391.
PMID: 37205123
PMC: 10185877.
DOI: 10.3389/fgene.2023.1181391.
Carboranes in drug discovery, chemical biology and molecular imaging.
Marfavi A, Kavianpour P, Rendina L
Nat Rev Chem. 2023; 6(7):486-504.
PMID: 37117309
DOI: 10.1038/s41570-022-00400-x.
Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies.
Fu Y, Snelder N, Guo T, van der Graaf P, van Hasselt J
Pharmaceutics. 2023; 15(4).
PMID: 37111660
PMC: 10143046.
DOI: 10.3390/pharmaceutics15041175.